Higher Cumulative Doses of Clomiphene Citrate Linked to Increased Miscarriage Risk Without Improving Live Birth Odds

A widely used fertility drug may carry a hidden tradeoff: as treatment accumulates across cycles, the risks may rise without improving the odds of a live birth. In a newly published study, researchers found that higher cumulative doses of clomiphene citrate查看药品详情—accumulated over multiple fertility treatment cycles—were associated with a progressively greater risk of pregnancy loss, while offering no corresponding improvement in the chance of a live birth.

Supported by the NHMRC and conducted in partnership with Boston University查看公司主页 and the Centers for Disease Control and Prevention (搜索)搜索该公司, the study analyzed 21,004 IVF embryo transfer cycles in the United States. The findings demonstrated a clear dose-response relationship: women receiving cumulative doses of 500–749 mg of clomiphene citrate查看药品详情 had a 12% higher risk of miscarriage (搜索)搜索该疾病, while those who received 750–999 mg had a 38% higher risk.

The pattern extended beyond miscarriage (搜索)搜索该疾病. Women receiving cumulative doses of 750 mg or more were more than twice as likely to have twins or other multiple births. The aim of fertility treatment is not simply to achieve pregnancy; specialists increasingly emphasize achieving one healthy birth at a time, since multiple pregnancies carry substantially greater health risks for mothers and babies.

Lead author Associate Professor Sheree Boulet said the study revealed a clear relationship between increasing exposure and risk. "Women who received higher cumulative doses of clomiphene citrate查看药品详情 experienced progressively greater risks of adverse pregnancy outcomes," Assoc. Prof. Boulet said. "We examined more than 21,000 embryo transfer cycles across four cumulative dose categories and found that increasing the dose did not significantly improve the chance of a live birth. Our findings suggest there may be a point where increasing the dose offers little additional benefit while exposing women to greater risk, highlighting the importance of carefully balancing effectiveness with safety when making treatment decisions."

Spontaneous abortion rates increased as dose increased. At the highest exposure level, stillbirth was more than three times as common; however, the researchers cautioned that this finding was not statistically significant because so few women received doses in this category, and larger studies are needed to confirm the association. The observation is nonetheless consistent with a previous publication from Adelaide University (搜索)搜索该词条 showing a doubling of neonatal death in pregnancies involving clomiphene citrate查看药品详情.

The findings build on a series of studies from Adelaide University (搜索)搜索该词条's Robinson Research Institute that linked clomiphene citrate查看药品详情 with increased risks of pregnancy loss, stillbirth, perinatal death, and some birth defects. Experimental studies in mice supported these findings, showing that higher doses reduced successful pregnancies and were associated with pregnancy loss, impaired fetal growth, and developmental abnormalities.

Clomiphene citrate查看药品详情 is one of the world's most widely prescribed fertility drugs. It has been prescribed to millions of women worldwide since 1967 and remains a recommended first-line treatment for ovulation induction. Recognized as an essential medicine by the World Health Organization, the drug works by stimulating the ovaries to release eggs, thereby increasing the chance of pregnancy. Women who do not respond to lower doses, or who require multiple treatment cycles, may receive progressively higher cumulative doses over time.

Current U.S. prescribing information recommends beginning with 50 mg a day for five days and increasing the dose only when ovulation does not occur. It also states that increasing treatment beyond 100 mg a day for five days is not recommended and that long-term cyclic treatment should generally not extend beyond about six cycles. The label further notes that once a woman ovulates at a given dose, increasing that dose in later cycles offers no advantage.

Senior researcher and co-author Professor Michael Davies said the study builds on more than two decades of Adelaide-led research examining the safety of fertility treatments. "Clomiphene citrate查看药品详情 has been used by many women since 1967, but it has never been comprehensively evaluated in large prospective clinical trials," Prof. Davies said. "Our studies indicate that women respond differently to clomiphene citrate and that increasing cumulative doses may increase the risk of adverse pregnancy outcomes without improving the likelihood of a live birth. The findings confirm and extend our previous studies in both human and mouse models which highlight the need to better understand the dose-response relationship and whether more personalized dosing strategies could improve safety."

"Until we can better understand these differences, it remains important that clinicians rigorously follow manufacturer's safety recommendations and avoid unnecessarily increasing cumulative doses," Prof. Davies added. "The same questions are now being asked of newer ovulation-inducing medications, so any move away from clomiphene citrate查看药品详情 should also be guided by robust evidence rather than assumptions about safety."